Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.

Drumm MR, Dixit KS, Grimm S, Kumthekar P, Lukas RV, Raizer JJ, Stupp R, Chheda MG, Kam KL, McCord M, Sachdev S, Kruser T, Steffens A, Javier R, McCortney K, Horbinski C.

Neuro Oncol. 2019 Nov 10. pii: noz216. doi: 10.1093/neuonc/noz216. [Epub ahead of print]

PMID:
31711239
2.

Pleomorphic xanthoastrocytoma: a brief review.

Shaikh N, Brahmbhatt N, Kruser TJ, Kam KL, Appin CL, Wadhwani N, Chandler J, Kumthekar P, Lukas RV.

CNS Oncol. 2019 Sep 19:CNS39. doi: 10.2217/cns-2019-0009. [Epub ahead of print]

3.

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.

Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaaw5680. doi: 10.1126/scitranslmed.aaw5680.

PMID:
31413142
4.

ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach.

Johnston SK, Whitmire P, Massey SC, Kumthekar P, Porter AB, Raghunand N, Gonzalez-Cuyar LF, Mrugala MM, Hawkins-Daarud A, Jackson PR, Hu LS, Sarkaria JN, Wang L, Gatenby RA, Egan KM, Canoll P, Swanson KR; ENDURES consortium.

Am J Clin Oncol. 2019 Aug;42(8):655-661. doi: 10.1097/COC.0000000000000564.

PMID:
31343422
5.

A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials.

Shaikh SS, Kumthekar PU, Mohindra NA.

J Neurooncol. 2019 Aug;144(1):235-237. doi: 10.1007/s11060-019-03219-7. Epub 2019 Jun 25. No abstract available.

PMID:
31240523
6.

Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study.

Ascha MS, Ostrom QT, Wright J, Kumthekar P, Bordeaux JS, Sloan AE, Schumacher FR, Kruchko C, Barnholtz-Sloan JS.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):917-925. doi: 10.1158/1055-9965.EPI-18-1116.

PMID:
31053636
7.

Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.

Lamano JB, Quaggin-Smith JA, Horbinski CM, Tate MC, Grimm SA, Kumthekar PU, Bloch O.

J Clin Neurosci. 2019 Jun;64:18-21. doi: 10.1016/j.jocn.2019.03.051. Epub 2019 Apr 1.

PMID:
30948314
8.

Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.

Lassman AB, Roberts-Rapp L, Sokolova I, Song M, Pestova E, Kular R, Mullen C, Zha Z, Lu X, Gomez E, Bhathena A, Maag D, Kumthekar P, Gan HK, Scott AM, Guseva M, Holen KD, Ansell PJ, van den Bent MJ.

Clin Cancer Res. 2019 Jun 1;25(11):3259-3265. doi: 10.1158/1078-0432.CCR-18-3034. Epub 2019 Feb 22.

PMID:
30796037
9.

Quality of Life of Family Caregivers of Patients With Cancer in Kor├že, Albania.

Judkins J, Laska I, Paice J, Kumthekar P.

J Palliat Care. 2019 Apr;34(2):118-125. doi: 10.1177/0825859718812432. Epub 2018 Nov 22.

PMID:
30465470
10.

Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease.

Kamath SD, Kumthekar PU.

Front Oncol. 2018 Sep 27;8:414. doi: 10.3389/fonc.2018.00414. eCollection 2018. Review.

11.

Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis.

Kamath SD, Kumthekar PU, Kruser TJ, Mohindra NA.

Oncologist. 2018 Dec;23(12):e159-e161. doi: 10.1634/theoncologist.2018-0022. Epub 2018 Aug 2.

PMID:
30072392
12.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091.

13.

Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma.

Bowman KM, Kumthekar P.

Future Oncol. 2018 Feb;14(4):391-407. doi: 10.2217/fon-2017-0255. Epub 2018 Jan 18. Review.

PMID:
29345149
14.

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A.

J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345. doi: 10.6004/jnccn.2017.0166.

PMID:
29118226
15.

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.

Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P.

Neuro Oncol. 2018 May 18;20(6):838-847. doi: 10.1093/neuonc/nox202.

16.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

17.

State-of-the-art considerations in small cell lung cancer brain metastases.

Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R.

Oncotarget. 2017 Jul 18;8(41):71223-71233. doi: 10.18632/oncotarget.19333. eCollection 2017 Sep 19. Review.

18.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC.

Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.

19.

Gene Delivery in Neuro-Oncology.

Dixit K, Kumthekar P.

Curr Oncol Rep. 2017 Sep 2;19(11):69. doi: 10.1007/s11912-017-0628-z. Review.

PMID:
28866732
20.

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.

Kumthekar P, Grimm S, Chandler J, Mehta M, Marymont M, Levy R, Muro K, Helenowski I, McCarthy K, Fountas L, Raizer J.

J Neurooncol. 2017 Jul;133(3):589-594. doi: 10.1007/s11060-017-2469-x. Epub 2017 May 16.

PMID:
28510787
21.

Mutant IDH1 and seizures in patients with glioma.

Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG, Pacione D, Golfinos JG, Kumthekar P, Ghamsari F, Chen L, Lein P, Chetkovich DM, Snuderl M, Horbinski C.

Neurology. 2017 May 9;88(19):1805-1813. doi: 10.1212/WNL.0000000000003911. Epub 2017 Apr 12.

22.

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.

Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ.

Cancer Treat Rev. 2017 Apr;55:10-15. doi: 10.1016/j.ctrv.2017.02.006. Epub 2017 Feb 22. Review.

PMID:
28279895
23.

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ.

Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532. Review.

PMID:
28177431
24.

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK.

Neuro Oncol. 2017 Jul 1;19(7):965-975. doi: 10.1093/neuonc/now257.

25.

Mutant IDH1 and thrombosis in gliomas.

Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, Chen R, Liu Y, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M, Horbinski C.

Acta Neuropathol. 2016 Dec;132(6):917-930. Epub 2016 Sep 23.

26.

Improving vaccine efficacy against malignant glioma.

Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, Binder DC, James CD, Wainwright DA.

Oncoimmunology. 2016 Jun 10;5(8):e1196311. doi: 10.1080/2162402X.2016.1196311. eCollection 2016 Aug. Review.

27.

Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.

Lukas RV, Kumthekar P, Rizvi S, Salgia R.

Future Oncol. 2016;12(8):1045-58. doi: 10.2217/fon.16.17. Epub 2016 Feb 18. Review.

PMID:
26888310
28.

Financial burden experienced by patients undergoing treatment for malignant gliomas.

Kumthekar P, Stell BV, Jacobs DI, Helenowski IB, Rademaker AW, Grimm SA, Bennett CL, Raizer JJ.

Neurooncol Pract. 2014 Jun;1(2):71-76. Epub 2014 May 5.

29.

Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden.

Jacobs DI, Kumthekar P, Stell BV, Grimm SA, Rademaker AW, Rice L, Chandler JP, Muro K, Marymont M, Helenowski IB, Wagner LI, Raizer JJ.

Neurooncol Pract. 2014 Jun;1(2):47-54. Epub 2014 May 5.

30.

Atypical meningioma: randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy.

Yoon H, Mehta MP, Perumal K, Helenowski IB, Chappell RJ, Akture E, Lin Y, Marymont MA, Sejpal S, Parsa A, Chandler JR, Bendok BR, Rosenow J, Salamat S, Kumthekar P, Raizer JK, Baskaya MK.

J Cancer Res Ther. 2015 Jan-Mar;11(1):59-66. doi: 10.4103/0973-1482.148708.

31.

Low-grade glioma.

Kumthekar P, Raizer J, Singh S.

Cancer Treat Res. 2015;163:75-87. doi: 10.1007/978-3-319-12048-5_5. Review.

PMID:
25468226
32.

A review of management strategies of malignant gliomas in the elderly population.

Kumthekar PU, Macrie BD, Singh SK, Kaur G, Chandler JP, Sejpal SV.

Am J Cancer Res. 2014 Sep 6;4(5):436-44. eCollection 2014. Review.

33.

Auditory hallucinations as ictal phenomena in a patient with voltage-gated potassium channel antibody-associated limbic encephalitis.

Boyd M, Attarian H, Raizer J, Kumthekar P, Macken MP, Schuele SU, Gerard E.

Epileptic Disord. 2013 Dec;15(4):433-6.

34.

Primary central nervous system lymphoma.

Doucet S, Kumthekar P, Raizer J.

Curr Treat Options Oncol. 2013 Jun;14(2):185-97. doi: 10.1007/s11864-013-0227-7.

PMID:
23456261
35.
36.

Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.

Kumthekar P, Grimm SA, Avram MJ, Kaklamani V, Helenowski I, Rademaker A, Cianfrocca M, Gradishar W, Patel J, Mulcahy M, McCarthy K, Raizer JJ.

J Neurooncol. 2013 Apr;112(2):247-55. doi: 10.1007/s11060-013-1055-0. Epub 2013 Jan 25.

PMID:
23354655
37.

Supplemental Content

Loading ...
Support Center